Industry Liaison Forum (ILF)
MISSION: Promote and facilitate the contribution of the biomedical industry to the global HIV response, focusing on expediting development and approval of HIV diagnostics and medicines.
The past decade has been marked by rapid advances in HIV research, leading to the introduction of new and more efficacious and client-friendly interventions for treating people living with HIV and preventing the further spread of the virus. Critical gaps remain in the development and expedient delivery of medical innovations to the people who most need them across the HIV cascade. The IAS Industry Liaison Forum (ILF) works to promote and facilitate the full contribution of the biomedical industry to the global HIV response by catalysing dialogue, engagement and, ultimately, action to address barriers along the HIV care continuum. By organizing a number of bespoke meetings on key topic areas, the ILF brings to the foreground the contribution of an interdisciplinary group on key thematic topics.
The ILF builds on its collaboration platform to address a range of pertinent issues, including:
- Paediatric HIV
Fast track the development of paediatric HIV medicines (focusing on the most-needed paediatric ARV formulations).
- Regulatory Affairs
Improve regulatory approval processes for timely access to quality HIV diagnostics and medicines by populations most in need.
This work is guided by a multi-stakeholder ILF Advisory Group made up of representatives from the HIV biomedical industry, as well as those outside this industry.
Learn more about the ILF Advisory Group and the corporate partnership programme
Enabling a generic manufacturer to begin work on a new drug for the paediatric market in parallel with the originator’s adult development programme could accelerate overall paediatric product development processes. This cross-company collaboration could indeed shorten timelines for development, clinical trials and approval of priority paediatric ARV formulations. There is a need to support the exploration of these kinds of innovative ideas by defining strategies to overcome potential intellectual property and regulatory barriers.
Overlapping regulatory requirements globally and across countries (including WHO Prequalification and national regulatory agencies) frequently require companies to conduct additional, sometimes duplicative, clinical trials and file multiple and different applications. In addition, some regulatory processes are inefficient, and their timelines are not always transparent. These issues lead to increases in development costs and delays before new diagnostic tools and medicines can be registered and used in country. Simplification and improvement of existing processes therefore represent opportunities to fast track access to quality diagnostics and medicines.
Inefficiencies in regulatory systems can be cause for both the delayed introduction of medical innovations onto the market and reduced access to those innovations for many of those who could benefit from them the most. The ILF is working to assess the WHO Prequalification of In Vitro Diagnostics and Medicines Programmes, as well as map out the programmes’ timelines from submission to final approval of commodities. Through this work, the ILF will advocate for improvements to these processes and increased transparency over their implementation.
Limited treatment options and suboptimal formulations have contributed to poor adherence and outcomes for children living with HIV. There is therefore a need to accelerate collaborative research and development efforts to increase the number and quality of treatment options available. Despite this, barriers to incentivizing research and development remain. There is a need for alternative models of collaboration and innovative financing mechanisms that build on existing regulatory processes, optimize investments and enable faster and sustainable development of prioritized products. This can be achieved with the implementation of a mechanism that would: accelerate the development and approval of new drugs; catalyse the development and market uptake of new child-friendly formulations of existing drugs; and provide sustainable financing to ensure the development of these new formulations. This Global Accelerator for Paediatric Formulations (GAP-f) is a new collaborative framework, including a set of recommendations for regulatory agencies and industry, and potentially supported by an innovative financing mechanism to fast track development of paediatric ARV formulations.
Ensuring, early on, that various industry perspectives are included in the development of the global accelerator is critical, as industry’s involvement is essential for the success of this initiative. The ILF leads this inclusion of the industry perspective in the development of a Global Accelerator for Paediatric Formulations (GAP-f), in collaboration with partner organizations.
During the 1994 Paris AIDS Summit, 42 countries declared the Greater Involvement of People living with HIV/AIDS (GIPA) as a cornerstone of the HIV response. Many stakeholders in HIV have found innovative ways to involve a diverse range of PLHIV and this has contributed to strengthened and improved responses acting on the links between HIV and human rights. GIPA has thereby contributed to addressing stigma and discrimination. Looking back, GIPA means two things at its core:
- The recognition that PLHIV have intimate knowledge of factors making people and communities vulnerable to HIV, as well as first-hand experience of the realities of living with HIV
- The creation of meaningful spaces within every aspect of the HIV response to include PLHIV in decision-making processes that affect their lives.
Engaging affected communities
Grounded in the belief that the GIPA principle promotes and guides the substantial and meaningful engagement of PLHIV at all levels of the HIV response, it is opportune to consider how deeply and widely GIPA is understood and implemented. To take stock of the current implementation of GIPA across the HIV biomedical industry sector in particular, the ILF has recently explored to what extent the GIPA principle is being implemented in the biomedical industry involved in HIV and associated diseases.
ILF Corporate Partners
The Industry Liaison Forum would like to thank its 2017 Corporate Partners:
See the list of previous industry partners | Learn about the ILF Corporate Partnership Programme